Title
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.

Permalink
https://escholarship.org/uc/item/51z268qb

Journal
British journal of cancer, 105(12)

ISSN
0007-0920

Authors
Stevens, KN
Garcia-Closas, M
Fredericksen, Z
et al.

Publication Date
2011-12-01

DOI
10.1038/bjc.2011.448

Peer reviewed
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

KN Stevens, M Garcia-Closas, Z Frederickson, M Kosel, VS Pankratz, JL Hopper, GS Dite, C Apicella, MC Southey, MK Schmidt, A Brooks, LJ Van’t Veer, RAEM Tollenar, PA Fasching, MW Beckmann, A Hein, AB Ekici, N Johnson, J Peto 1, I dos Santos Silva, L Gibson, E Sawyer, I Tomlinson, MJ Kerin, S Chanock, J Lissowska, DJ Hunter, RN Hoover, GD Thomas, RL Milne, JI Arias Pérez, A González-Neira, J Benitez, B Burwinkel, A Meindl, RK Schmutzler, CR Bartram, U Hamann, YD Ko, T Brünning, J Chang-Claude, R Hein, S Wang-Gohrke, T Đörk, P Schürmann, M Bremer, P Hillelmanns, N Bogdanova, JVL Zalutsky, YI Rogov, N Antonenkova, A Lindblom, S Margolin, A Mannermaa, V Kataja, V-M Kosma, J Hartikainen, G Chenevix-Trench, X Chen, P Peterlongo, B Bonanni, L Bernard, S Manoukian, X Wang, J Cerhan, CM Yachou, J Olson, GG Giles, L Baglietto, CA Mealan, G Severi, EM John, A Miron, R Winqvist, K Pyllä, A Jukkola-Yuorinen, M Grip, I Andrushko, JA Knight, G Glendon, AM Mulligan, A Cox, IW Brock, G Elliott, SS Cross, PP Pharaoh, AM Dunning, KA Pooley, MK Humphreys, J Wang, D Kang, K-Y Yoo, D-N Yoh, S Sangrajrung, V Gabriele, P Brennan, J McKay, H Anton-Culver, A Ziogas, FJ Couch, and DF Easton.

The GENICA Network, kConFab Investigators, Australian Ovarian Cancer Study Group.

1Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; 2Sections of Epidemiology and Genetics, Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, 123 Old Brompton Road, London SW7 3RP, UK; 3Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Victoria 3010, Australia; 4Department of Pathology, The University of Melbourne, Victoria 3010, Australia; 5The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; 6Leiden University Medical Center, Atrium 250, 2333 ZA, Leiden, The Netherlands; 7Division of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; 8Department of Gynecology and Obstetrics, University Breast Center Francusia, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Schloßplatz 4, 91054 Erlangen, Germany; 9Institute of Human Genetics, Friedrich-Alexander University Erlangen-Nuremberg, Schloßplatz 4, 91054 Erlangen, Germany; 10Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA; 11Section of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA; 12Section of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA; 13Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK; 14Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; 15National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK; 16Oxford Biomedical Research Centre, Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; 17NUIB Department of Surgery, Clinical Science Institute, University Hospital Galway, Galway 091 524 411, Ireland; 18Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7242, Bethesda, MD 20892-7335, USA; 19Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Memorial Cancer Center, Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland; 20Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA; 21Section of Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; 22Servicio de Cirugía General y Especialidades, Hospital Monte Naranjo, Av. Doctores Fernández Vega 107, Oviedo 33012, Spain; 23Human Genotyping Unit (CeGen), Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; 24Department of Obstetrics and Gynaecology, University Hospital Heidelberg, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 25Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 26Department of Gynaecology and Obstetrics, Technical University of Munich, Arcisstraße 21, 80333 Munich, Germany; 27Division of Molecular Oncology, Department of Gynaecology and Obstetrics, Center of Molecular Medicine Cologne (CMMCO), University Hospital of Cologne, 50931 Cologne, Germany; 28Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany; 29Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 30Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Betriebsstätte Johanner Krankenhaus, Johannerstraße 3-5, 53113 Bonn, Germany; 31Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (BPA), Burdastrasse, 1, 44789 Bochum, Germany; 32Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 33Department of Obstetrics and Gynaecology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany; 34Hannover Medical School, Gynaecology Research Unit, 30625 Hannover, Germany; 35Department of Oncology, University of Eastern Finland and Kuopio University Hospital, Biocenter Kuopio, FI-70211 Kuopio, Finland; 36Institute of Clinical Medicine, Department of Oncology, University of Eastern Finland; 37Institute of Medical Research, 300 Herston Road, Herston, QLD 4029, Australia; 38Centre for Medical Research (NIHR) Comprehensive Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK; 39Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, 123 Old Brompton Road, London SW7 3RP, UK; 40Department of Medicine, University of Melbourne, Victoria 3010, Australia; 41Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7242, Bethesda, MD 20892-7335, USA; 42Section of Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; 43Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Memorial Cancer Center, Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland; 44Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA; 45Section of Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; 46Department of Obstetrics and Gynecology, University Hospital Heidelberg, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 47Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 48Department of Gynaecology and Obstetrics, Technical University of Munich, Arcisstraße 21, 80333 Munich, Germany; 49Division of Molecular Oncology, Department of Gynaecology and Obstetrics, Center of Molecular Medicine Cologne (CMMCO), University Hospital of Cologne, 50931 Cologne, Germany; 50Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany; 51Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 52Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Betriebsstätte Johanner Krankenhaus, Johannerstraße 3-5, 53113 Bonn, Germany; 53Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (BPA), Burdastrasse, 1, 44789 Bochum, Germany; 54Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; 55Department of Obstetrics and Gynaecology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany; 56Hannover Medical School, Gynaecology Research Unit, 30625 Hannover, Germany; 57Hannover Medical School, Clinics of Radiation Oncology, 30625 Hannover, Germany; 58Hannover Medical School, Clinics of Obstetrics and Gynaecology, 30625 Hannover, Germany; 59Department of Molecular Medicine and Surgery, Karolinska Institutet, S17176 Stockholm, Sweden; 60Department of Oncology Pathology, Karolinska Institutet, S17176 Stockholm, Sweden; 61Institute of Clinical Medicine, Department of Pathology, University of Eastern Finland and Kuopio University Hospital, Biocenter Kuopio, FI-70211 Kuopio, Finland; 62Institute of Clinical Medicine, Department of Oncology, University of Eastern Finland; 63Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4029, Australia.
Phosphatidylinositol-3-kinases (PI3Ks) constitute a lipid kinase family integral to signalling pathways that regulate many cancer-related processes, including cell proliferation, adhesion, apoptosis, survival and motility (Fruman et al, 1998; Cantley, 2002). Alteration of PI3K family members, such as amplification of the phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) oncogene on chromosome 3q26 that encodes the p110α catalytic subunit of PI3K, are commonly observed in human cancers. Amplification and overexpression of PIK3CA results in increased production of the phosphatidylinositol-3,4,5-triphosphate second messenger, hyperactivation of the PI3K/AKT pathway, and stimulation of cellular transformation and tumour progression (Shayesteh et al, 1999; Ma et al, 2000; Fresno Vara et al, 2004; Saal et al, 2005; Samuels and Ericson, 2008). Somatic mutations in PIK3CA are also common in colon (18–32%), gastric (4–25%), endometrial (36%), liver (36%), brain (27%) and breast (18–40%) tumours (Bachman et al, 2004; Campbell et al, 2004; Samuels et al, 2004; Karakas et al, 2006; Ligresti et al, 2009). Functional analyses have shown that many of these mutations activate PIK3CA enzymatic activity and stimulate downstream AKT signalling, promoting growth factor-independent growth and metastasis (Samuels et al, 2004; Samuels and Ericson, 2006).

In breast tumours, PIK3CA mutations have been consistently associated with ER-positive and human epidermal growth factor receptor-2 (HER2)-positive tumour status (Saal et al, 2005; Li et al, 2006; Perez-Tenorio et al, 2007; Stemke-Hale et al, 2008) (Saal et al, 2005; Perez-Tenorio et al, 2007). The correlation between these mutations and breast cancer prognosis is less clear, with several studies reporting associations between PIK3CA mutations and lymph node metastasis and worse overall and breast-cancer-specific survival (Saal et al, 2005; Li et al, 2006; Lai et al, 2008; Aleskandarany et al, 2010), whereas other studies have
reported associations with longer survival particularly among patients with ER-positive, HER2-negative tumours (Perez-Tenorio et al., 2007; Kalinsky et al., 2009; Loi et al., 2010). Although the pathological and clinical significance of PIK3CA somatic mutations has been well studied, the contribution of inherited variation in this important oncogene to risk of breast cancer is unknown. Here we investigated the influence of germline variation in PIK3CA on breast cancer risk.

MATERIALS AND METHODS

Mayo clinic breast cancer study

The details of the Mayo Clinic Breast Cancer case–control Study (MCBCS) have been described previously (Wang et al., 2008). Briefly, cases were comprised of Caucasian women with invasive breast cancer diagnosed within 6 months of ascertainment with no prior history of cancer. Controls were comprised of Caucasian women visiting the Mayo Clinic for general medical exams in the Department of Internal Medicine with no prior history of cancer. Participants were recruited under an Institutional Review Board approved protocol. A total of 798 cases and 843 controls were utilised for stage 1 genotyping (Table 1).

Replication studies

The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer case–control study and 26 case–control studies from Breast Cancer Association Consortium (BCAC) contributed data to these analyses (described in Supplementary Table 1). Stage 1 of the CGEMS GWAS included 1145 cases and 1142 controls of self-reported white European ancestry (Thomas et al., 2009), whereas the combined Stage 1 and 2 of CGEMS included a total of 5436 cases and 5280 controls (Table 1). The BCAC replication was comprised of 24 studies of women of primarily European descent (Supplementary Table 1), 1702 additional samples from MCBCS and two studies (SEBCS and TBCS) of women from Southeast Asia (Table 1). Final combined analyses included 35 991 breast cancer cases and 26 case–control studies from MCBCS and CGEMS (Supplementary Table 1), 1702 additional samples from MCBCS and two studies (SEBCS and TBCS) of women from Southeast Asia (Stage 2: Cancer Genetic Markers of Susceptibility study). Includes Stage 1: Mayo Clinic Breast Cancer Study.

Genotyping

Four haplotype-tagging single-nucleotide polymorphisms (SNPs) within PIK3CA (rs13320257, rs3729692, rs1607237, rs9838117) were selected (r² > 0.80 in European–American genotype data from HapMap release 21). A total of 1741 Mayo Clinic samples (798 cases, 843 controls and 100 duplicates) were genotyped on custom oligo pool assays at Illumina Corporation (San Diego, CA, USA) using the Illumina GoldenGate assay. All SNPs had genotype call rates > 95%. Concordance between duplicate samples was 100%. Genotyping of rs1607237 in CGEMS and BCAC was performed using a TaqMan allelic discrimination assay or the Sequenom platform (Sequenom, San Diego, CA, USA) via standard protocols. Genotyping concordance was verified with internal duplicates and overall data quality was ensured using independent genotyping of 96 CEU samples by each genotyping center (Garcia-Closas et al., 2008). All studies met the specified criteria for call rate (> 95%).

Pathology and tumour markers

The collection of pathology and tumour marker information for BCAC has been described previously (Yang et al., 2011). Pathology data were also available for 900 CGEMS subjects. Briefly, studies provided information on histopathological subtype, grade of differentiation, tumour size, nodal involvement and stage at diagnosis of breast tumours. All studies except BBCS, GC-HBOC and HMBCS provided data on ER and progesterone receptor (PR) status of tumours, and 12 studies provided data on HER2 (Supplementary Table 2). ER/PR status was most commonly defined using data from medical records. Oestrogen receptor and PR negative status was defined as <10% of the tumour cells stained. Human epidermal growth factor receptor-2-negative status was typically defined as a score of 0 or 1+ on a HER2 immunohistochemistry (IHC) scale of 0–3 +.

Statistical methods

Evidence of departure from Hardy–Weinberg equilibrium (HWE) was assessed in controls using a goodness of fit test and none was observed (HWE P ≥ 0.001). Single-nucleotide polymorphism associations were tested using unconditional logistic regression adjusting for age and state of residence in a log-additive model. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) separately for heterozygotes and rare homozygotes. The association between rs1607237 and breast cancer risk in stage 1 of the CGEMS GWAS was evaluated as previously described (Thomas et al., 2009). Associations with breast cancer risk in the BCAC studies and the combined BCAC, MCBCS and CGEMS studies were evaluated using unconditional logistic regression adjusting for study center. A likelihood ratio test of heterogeneity adjusting for age did not change the results. Analyses of pathology-specific subsets of cases were conducted using polytomous regression with controls as the reference outcome, adjusting for study site.

| Study* | Country | Cases n (%) | Controls n (%) |
|--------|---------|-------------|----------------|
| ABCFS  | Australia | 1199 (3.1) | 438 (1.2) |
| ABCS   | The Netherlands | 1465 (3.8) | 548 (1.5) |
| BBCC   | Germany | 1060 (2.8) | 994 (2.7) |
| BBCS   | UK | 1153 (3.0) | 831 (2.3) |
| BIGGS  | Ireland | 1060 (2.8) | 900 (2.5) |
| CGEMS* | USA | 5436 (14.2) | 5280 (14.4) |
| CNIO-BCS | Spain | 752 (2.0) | 823 (2.2) |
| GC-HBOC | Germany | 864 (2.3) | 1224 (3.3) |
| GENICA | Germany | 1013 (2.7) | 1012 (2.8) |
| GESBC  | Germany | 563 (1.5) | 564 (1.5) |
| HABCs  | Germany | 1046 (2.7) | 998 (2.7) |
| HMBCS  | Belarus | 1760 (4.6) | 1015 (2.8) |
| KARBC  | Sweden | 812 (2.1) | 863 (2.4) |
| kConFab/AOCS | Australia/New Zealand | 566 (1.5) | 899 (2.5) |
| KBCP   | Finland | 485 (1.3) | 427 (1.2) |
| MARIE  | Germany | 2754 (7.2) | 5302 (14.5) |
| MBCSG  | Italy | 739 (1.9) | 1231 (3.4) |
| MCBCS* | USA | 1789 (4.7) | 1554 (4.2) |
| MCCS   | Australia | 679 (1.8) | 751 (2.1) |
| NC-BCRF | USA | 388 (1.0) | 154 (0.4) |
| OBCS   | Finland | 544 (1.4) | 509 (1.4) |
| OFBCR  | Canada | 1170 (3.1) | 329 (0.9) |
| SBCS   | UK | 1217 (3.2) | 1201 (3.3) |
| SEARCH | UK | 6520 (17.1) | 6779 (18.5) |
| SEBCS* | Korea | 1732 (4.5) | 1178 (3.2) |
| TBCS*  | Thailand | 451 (1.2) | 291 (0.8) |
| UCIBCS | USA | 957 (2.5) | 527 (1.4) |
| Total  |          | 38 174 (100) | 36 622 (100) |

*See Supplementary Table 1 for definition of study acronyms. 1. Stage 2: Cancer Genetic Markers of Susceptibility study. Includes Stage 1: Mayo Clinic Breast Cancer Study. 2. Asian case–control studies.
RESULTS

Of four PIK3CA haplotype-tagging SNPs, rs1607237 was significantly associated with risk of breast cancer in MCBCS (OR = 0.85, 95% CI 0.73–0.98, \( P = 0.023 \); Table 2, Supplementary Figure 1). Next we evaluated associations between rs1607237 and breast cancer risk in 1145 cases and 1142 controls genotyped in stage 1 of the CGEMS breast cancer GWAS (Thomas et al, 2009). Rs1607237 was significantly associated with breast cancer risk (heterozygous OR = 1.12, homozygous OR = 0.79, score \( P = 0.017 \)). To provide a more stable estimate of risk in this population, 8429 additional CGEMS subjects were genotyped for rs1607237. In all 5436 cases and 5280 controls from stage 1 and 2 of CGEMS, rs1607237 was strongly associated with a decrease in breast cancer risk (OR = 0.92, 95% CI 0.88–0.98, \( P = 0.0500 \); Table 2).

This finding provided the rationale for further evaluation of this SNP in 23 BCAC studies involving women of European ancestry (28766 cases, 28319 controls), and two BCAC studies of Asian women (2183 cases, 1469 controls; Table 1). Rs1607237 was not significantly associated with breast cancer risk in the 23 BCAC studies of women of European ancestry (OR = 0.98, 95% CI 0.96–1.01, \( P = 0.139 \)) or in the two Asian BCAC studies (OR = 1.05, 95% CI 0.94–1.16, \( P = 0.39 \); Table 2). However, when combining all genotype data from the three stages of this study (MCBCS, CGEMS and BCAC; Supplementary Table 3), rs1607237 was significantly associated with risk of breast cancer (OR = 0.97, 95% CI 0.95–0.99, \( P = 9.5 \times 10^{-5} \)). Similarly, a significant association was observed when considering only women of European ancestry in the combined analysis (OR = 0.97, 95% CI 0.95–0.99, \( P = 4.6 \times 10^{-5} \); Table 2). There was no evidence of heterogeneity by study among the 25 Caucasian studies (\( P = 0.14 \); Supplementary Figure 2).

To further understand the association with breast cancer, we restricted the analysis to women with invasive breast cancer. Rs1607237 was associated with a reduced risk of invasive breast cancer (OR = 0.97, 95% CI 0.95–0.99, \( P = 0.012 \); Table 2), whereas no association with risk of ductal carcinoma in situ was observed (OR = 0.93, 95% CI 0.85–1.02, \( P = 0.12 \)). In addition, we explored differences in PIK3CA SNP associations in the combined data set by tumour subtype (Supplementary Table 4). The rs1607237 variant was not associated with any subtypes defined by ER, PR or HER2 status, although it is important to note the reduction in sample size when restricting to these tumour subtypes.

DISCUSSION

Here we report an association between inherited variation in the oncogene PIK3CA and risk of breast cancer in a large, three-stage analysis utilising nearly 75,000 subjects from 27 case–control study studies. We show that rs1607237 is significantly associated with a small decrease in breast cancer risk (OR = 0.97, 95% CI 0.95–0.99, \( P = 9.5 \times 10^{-5} \)) in all studies combined and when considering only women of European ancestry in the combined studies (OR = 0.97, 95% CI 0.95–0.99, \( P = 4.6 \times 10^{-5} \)). However, the association did not achieve significance in the large third stage involving only BCAC studies. Although the first two stages of our analysis suggest an association between PIK3CA and breast cancer risk, our inability to confirm this finding in the BCAC studies suggests that the result should be interpreted with caution.

We further explored the linkage disequilibrium patterns in the PIK3CA coding and promoter regions to better understand the relationship between rs1607237 and other variation in this region. Rs1607237 was not in strong linkage disequilibrium with two non-synonymous polymorphic variants in the coding region of PIK3CA, rs1051399 (\( r^2 = 0.0060 \)) and rs3729680 (\( r^2 = 0.034 \)), which had been genotyped in HapMap samples of European ancestry. However, an additional 18 non-synonymous variants were either not polymorphic or had not been genotyped in the HapMap samples, making inference about the relationship between rs1607237 and all variants of unknown significance in the PIK3CA coding region difficult. In addition, two PIK3CA promoter SNPs were in low LD with rs1607237 (rs9831234, \( r^2 = 0.16 \); rs2865084, \( r^2 = 0.038 \)). However, it remains possible that PIK3CA promoter SNPs that were not captured in this study are related to breast cancer risk.

It is also important to note that the effect estimate for rs1607237 in the BCAC replication studies and in the overall BCAC, MCBCS and CGEMS studies is quite small (OR = 0.97). This limits our statistical power to detect significant associations in these studies despite the large sample size, particularly in analyses utilising pathology information that is available for only a subset of subjects. Similarly, we had limited power to detect associations in the original MCBCS study with the three non-significant PIK3CA SNPs. Thus, it remains possible that evaluation of these variants in the larger BCAC cohort might detect associations with risk. While the effect of rs1607237 on risk is small, the association between inherited variation in this important oncogene and breast cancer risk does provide valuable biological insight into the development of this disease. Validation of rs1607237 in GWAS studies from other large collaborative groups and additional studies by BCAC with detailed pathology information are necessary to confirm this association. Functional evaluation of this variant is needed to fully understand the relationship between inherited PIK3CA variation and breast cancer risk.

ACKNOWLEDGEMENTS

The ABCS study was funded by the Dutch Cancer Society (grants NKI 2001-2423; NKI 2007-3839), the Dutch National Genomics

© 2011 Cancer Research UK
Initiative; ABCS acknowledges all patients, and Sten Cornelissen, Richard van Hien, Flora van Leeuwen, Vincent Smit and other contributors to the 'BOCIS' study (ABCS). The ABCFS, NC-BCFR and OFBCR works were supported by the United States National Cancer Institute, National Institutes of Health (NIH) under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Northern California Cancer Center (U01 CA69417), University of Melbourne (U01 CA69638). Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. JHL is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. MCS is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. BBCC is funded in part by the ELAN fund of the University Hospital Erlangen. The BBCC is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NHMRC Biomedical Research Centres and the National Cancer Research Network (NCRN). ES is supported by NHMRC Comprehensive Biomedical Research Centre, Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The CNIO-BCS was supported by the Genome Spain Foundation, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI081583 and PI081120). We thank Charo Alonso, Tais Moreno, Guillermo Menéndez and Pilar Zamora for their contribution to this work. The GC-HBCO was collected within a project funded by the Deutsche Krebshilfe (Grant number: 107054). It was supported by the Dietmar-Hopp Foundation, the Helmholtz society and the German Cancer Research Centre (DKFZ). We thank Sandrine Tchatrou for genotyping. The HABCS was supported by an intramural grant from Hannover Medical School. The HMBCS was supported by short-term fellowships from the German Academic Exchange Program (to NB), and the Friends of Hannover Medical School (to NB). KARBAC acknowledges The Swedish Cancer Society and The Stockholm Cancer Society. KBCP is supported by grants from the Finnish Cancer Society; The Academy of Finland (grant number 127220); the special Government Funding (EVO) of Kuopio University Hospital (grant number 5654113 and 3501) and by the strategic funding of the University of Eastern Finland. We thank Mrs Helena Kemiläinen, Mrs Aiia Parkkinnen and Mrs Eija Myöhänen for their skillful technical assistance. We thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001–2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia Financial support for the AOCs was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729); the Cancer Council of Tasmania and Cancer Foundation of Western Australia; and the NHMRC [199600]. GC-T is supported by funds from Italian citizens who allocated the 5 × 1000 share of their tax payment to the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects ’5 × 1000’). MBCSG thanks Paolo Radice, Bernard Peissel, Daniela Zaffaroni and Marco A Pierotti of the Fondazione IRCCS Istituto Nazionale Tumori and Monica Barile of the Istituto Europeo di Oncologia, Milano, Italy. MCBCS was supported by NIH grant CA122340 and US Recovery act award CA122340Z. Many people have contributed to the MCCS, including the original investigators and the diligent teams who recruited the participants and who continue working on follow-up. Finally, we express our gratitude to the many thousands of Melbourne residents who continue to participate in the study. Cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. OBCS was supported by research grants from the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the Academy of Finland, the University of Oulu and the Oulu University Hospital. SBSC was funded by the Breast Cancer Campaign and Yorkshire Cancer Research. The authors acknowledge Helen Cramp, Sue Higham, Dan Connelly, Saba Balasubramaniam. The UCIBCS is supported by the National Institutes of Health, National Cancer Institute grants CA-58860, CA-92044 and the Lon V Smith Foundation grant LVS-39420.

Conflict of interest
The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES
Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122(1): 45–53
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Park BH, Velculescu VE, Park BH (2004) The PIK3CA gene in ovarian cancer. Cancer Res 64(21): 7678–7681
Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hous CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21): 7678–7681
Chenevix-Trench G, Spurdle AB, Breslow NE, et al (2011) PIK3CA common variants and breast cancer risk. Annu Rev Biochem 80: 481–507
Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu Rev Biochem 67: 481–507
Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2): 193–204
Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richardson DA, Bojesen SE, Nordestgaard BG, Axelson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillelmanns P, Bogdanova N, Bremer M, Kastrens JH, Fagerholm R, Aaltonen K, Aittomaki K, von Smitten K, Biomqivist C, Manneaxma A, Uusitupa M, Eskeleen M, Tengstrom M, Kosma VM, Kataja V, Chenex-French G, Spurde AB, Breslow NE, Chen X, Devilee P, van...
APPENDIX

The GENICA Network

Gene Environment Interaction and Breast Cancer in Germany (GENICA): Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University Tübingen, Germany (Hiltrud Brauch, Christina Justenhoven); Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (UH); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YDK, Christian Biald); Institute of Pathology, Medical Faculty of the University of Bonn, Germany (Hans-Peter Fischer); Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany (TB, Beate Pesch, Volker Harth, Sylvia Rabstein). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group. This work is published under the standard license to publish-NonCommercial-Share Alike 3.0 Unported License. The GENICA was provided with funding by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK975/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. kConFab Investigators, Australian Ovarian Cancer Study Group.